71 related articles for article (PubMed ID: 29719934)
1. Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study.
Yoshida C; Yamaguchi H; Doki N; Murai K; Iino M; Hatta Y; Onizuka M; Yokose N; Fujimaki K; Hagihara M; Oshikawa G; Murayama K; Kumagai T; Kimura S; Najima Y; Iriyama N; Tsutsumi I; Oba K; Kojima H; Sakamaki H; Inokuchi K;
Int J Hematol; 2023 May; 117(5):694-705. PubMed ID: 36739328
[TBL] [Abstract][Full Text] [Related]
2. Analysis of drug transporter gene polymorphisms in an elderly patient with chronic myeloid leukemia successfully treated with intermittent low-dose dasatinib.
Nakamura Y; Hidaka D; Ogasawara R; Okada K; Sugita J; Sukehata A; Kitagawa K; Ota S; Imamura M
Geriatr Gerontol Int; 2023 Dec; 23(12):965-966. PubMed ID: 37920916
[No Abstract] [Full Text] [Related]
3. BioCode gold-nanobeacon for the detection of fusion transcripts causing chronic myeloid leukemia.
Cordeiro M; Giestas L; Lima JC; Baptista PM
J Nanobiotechnology; 2016 May; 14(1):38. PubMed ID: 27185032
[TBL] [Abstract][Full Text] [Related]
4. Chronic myeloid leukaemia with soft tissue mass formed by mature granulocytes.
Koto S; Kanda Y; Ohnou N; Morita Y
BMJ Case Rep; 2024 Jun; 17(6):. PubMed ID: 38844352
[TBL] [Abstract][Full Text] [Related]
5. Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials.
Shin DY; Park S; Jang E; Kong JH; Won YW; Oh S; Choi Y; Kim JA; Lee SW; Mun YC; Kim H; Kim SH; Rok Do Y; Kwak JY; Kim HJ; Zang DY; Lim SN; Lee WS; Kim DW
Leuk Res; 2024 Jun; 143():107542. PubMed ID: 38924942
[TBL] [Abstract][Full Text] [Related]
6. Signaling Microdomains in the Spotlight: Visualizing Compartmentalized Signaling Using Genetically Encoded Fluorescent Biosensors.
Zhang JF; Mehta S; Zhang J
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():587-608. PubMed ID: 33411579
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
8. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
Fava C; Rege-Cambrin G; Dogliotti I; Gottardi E; Berchialla P; Di Gioacchino B; Crasto F; Lorenzatti R; Volpengo A; Daraio F; Fantino C; Saglio G
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S96-S100. PubMed ID: 27131622
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment evaluation of fluorescence resonance energy transfer-based drug sensitivity test for patients with chronic myelogenous leukemia treated with dasatinib.
Kondo T; Fujioka M; Tsuda M; Murai K; Yamaguchi K; Miyagishima T; Shindo M; Nagashima T; Wakasa K; Fujimoto N; Yamamoto S; Yonezumi M; Saito S; Sato S; Ogawa K; Chou T; Watanabe R; Kato Y; Takahashi S; Okano Y; Yamamoto J; Ohta M; Iijima H; Oba K; Kishino S; Sakamoto J; Ishida Y; Ohba Y; Teshima T;
Cancer Sci; 2018 Jul; 109(7):2256-2265. PubMed ID: 29719934
[TBL] [Abstract][Full Text] [Related]
10. A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells.
Mizutani T; Kondo T; Darmanin S; Tsuda M; Tanaka S; Tobiume M; Asaka M; Ohba Y
Clin Cancer Res; 2010 Aug; 16(15):3964-75. PubMed ID: 20670950
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of first-line nilotinib therapy and evaluation of the clinical utility of the FRET-based drug sensitivity test.
Kondo T; Fujioka M; Fujisawa S; Sato K; Tsuda M; Miyagishima T; Mori A; Iwasaki H; Kakinoki Y; Yamamoto S; Haseyama Y; Ando S; Shindo M; Ota S; Kurosawa M; Ohba Y; Teshima T;
Int J Hematol; 2019 Oct; 110(4):482-489. PubMed ID: 31240558
[TBL] [Abstract][Full Text] [Related]
12. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.
Takaku T; Iriyama N; Mitsumori T; Sato E; Gotoh A; Kirito K; Noguchi M; Koike M; Sakamoto J; Oba K; Komatsu N
Oncology; 2018; 94(2):85-91. PubMed ID: 29151104
[TBL] [Abstract][Full Text] [Related]
13. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
